Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Obinutuzumab and CC-99282 for the Treatment of Patients with Previously Untreated High Tumor Burden Follicular Lymphoma

Trial Status: active

This phase II trial tests the safety and effectiveness of obinutuzumab and CC-99282 in treating patients with previously untreated, high tumor burden follicular lymphoma. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of cancer cells to grown and spread. Giving obinutuzumab and CC-99282 in combination may be effective at controlling disease in patients with previously untreated follicular lymphoma.